The Small Molecule Active Pharmaceutical Ingredient Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Small Molecule Active Pharmaceutical Ingredient Market:
According to The Business Research Company’s Small Molecule Active Pharmaceutical Ingredient Global Market Report 2024, The small molecule active pharmaceutical ingredient market size has grown strongly in recent years. It will grow from $181.54 billion in 2023 to $196.44 billion in 2024 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to regulatory approvals, patent expirations, disease prevalence, pricing pressures, clinical trial outcomes.
The small molecule active pharmaceutical ingredient market size is expected to see strong growth in the next few years. It will grow to $265.6 billion in 2028 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to precision medicine, specialty therapeutics, sustainability initiatives, telehealth adoption, integration of AI. Major trends in the forecast period include outsourcing trends, targeted therapies, digitalization in pharma, virtual clinical trials, advanced analytics.
The increasing prevalence of diseases is a major driver propelling the small molecule active pharmaceutical ingredient (API) market. A disease is a particular abnormal condition, a disorder of a structure or function, that affects the body of the patient. Active pharmaceutical ingredients (APIs) are the active components in a pharmaceutical drug that produce the required effect on the body to treat various conditions. For instance, according to Cancer Research UK, a UK-based cancer research organization, approximately 18 million new cancer cases were detected in 2020. Further, there would be 28 million new cancer cases globally each year by 2040, a 54.9% increase over 2020, and is predicted to be more prominent in males (60.6% increase) than girls (48.8% increase). Further, in March 2023, according to the reports shared by the American Society of Clinical Oncology (ASCO), a US-based professional organization, it was estimated that more than 12,000 people in the US were diagnosed with neuroendocrine tumors yearly. Further, approximately 171,000 people were living with this diagnosis in 2023. Cardiovascular diseases have resulted in the deaths of 17.9 million people worldwide. Therefore, the increasing prevalence of diseases will continue to be the key driver in the small molecule API market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=7948&type=smp
The small molecule active pharmaceuticals market covered in this report is segmented –
1) By Type: Synthetic, Chemical, Biological
2) By Therapeutic Type: Autoimmune Diseases, Oncology, Metabolic Diseases, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Neurology, Respiratory Disorders, Dermatology, Urology
3) By Manufacturing Method: In-House, Contract
4) By Application: Clinical, Commercial
Major companies operating in the small molecule API market are developing new technologies such as microparticle technologies to gain a competitive edge in the market. Microparticle technology refers to the development and manipulation of particles at the micrometer scale, typically ranging in size from 1 to 1000 micrometers. For instance, in March 2022, Evonik Industries AG, a Germany-based specialty chemical company, launched the EUDRATEC SoluFlow, designed to significantly enhance the solubility of active pharmaceutical ingredients in oral drug products. This emulsion-based process technology addresses challenges related to drug solubility, particularly for compounds that were previously considered insoluble, opening new possibilities for the development of oral therapeutics in areas such as cancer, cardiovascular diseases, infectious diseases, and diabetes. EUDRATEC SoluFlow transforms poorly soluble drugs into free-flowing powders of amorphous solid dispersions, simplifying manufacturing processes and offering improved pharmacokinetic performance, thereby expanding the potential for developing more effective and accessible oral medications.
The small molecule active pharmaceutical ingredient market report table of contents includes:
- Executive Summary
- Small Molecule Active Pharmaceutical Ingredient Market Characteristics
- Small Molecule Active Pharmaceutical Ingredient Market Trends And Strategies
- Small Molecule Active Pharmaceutical Ingredient Market - Macro Economic Scenario
- Global Small Molecule Active Pharmaceutical Ingredient Market Size and Growth
.
.
.
- Global Small Molecule Active Pharmaceutical Ingredient Market Competitive Benchmarking
- Global Small Molecule Active Pharmaceutical Ingredient Market Competitive Dashboard
- Key Mergers And Acquisitions In Small Molecule Active Pharmaceutical Ingredient Market
- Small Molecule Active Pharmaceutical Ingredient Market Future Outlook and Potential Analysis
- Appendix
Top Major Players :
- Pfizer Inc.
- BASF SE
- Roche Holding AG
- Hoffmann-La Roche Limited
- AbbVie Inc.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
